Efficacy and Safety of Dupilumab Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids

Inclusion Criteria: * Patients affiliated to a social insurance protection regimen. * Patients with moderate to severe chronic (\>6 months) hand eczema with an Investigator global assessment (IGA) of 3 or 4 (out of a scale of 0 to 4). * Patients intolerant (according to the physician) or resistant to highly potent topical corticosteroids. Inadequate response (resistance) to highly potent topical corticosteroids is defined as a history of failure to achieve and maintain remission or a low disease activity state (comparable to an IGA score of 0 \[indicating clear\] to 2 \[indicating mild\]) despite treatment with a daily regimen of highly potent topical corticosteroids applied for 14 days or for the maximum duration recommended for highly potent topical corticosteroids. * Patients who are able to understand the study procedures including the ability to complete patient-oriented questionnaires. * Patients who are able to apply a stable dose of emollients within 7 days before the baseline visit. * Patients who agree to sign the written informed consent. Exclusion Criteria: * Hypersensitivity to dupilumab or to any of its ingredients * Patients under adult autonomy protection system * Any other condition (e;g., psoriasis) on the hands that according to the investigator will impair the ability to evaluate treatment effect. * Treatment with topical corticosteroids or topical calcineurin inhibitors within one week of baseline. * Treatment with oral immunosuppressants (including cy…